Literature DB >> 1346392

Alpha 2-C10 adrenergic receptors expressed in rat 1 fibroblasts can regulate both adenylylcyclase and phospholipase D-mediated hydrolysis of phosphatidylcholine by interacting with pertussis toxin-sensitive guanine nucleotide-binding proteins.

E E MacNulty1, S J McClue, I C Carr, T Jess, M J Wakelam, G Milligan.   

Abstract

The alpha 2-C10 adrenergic receptor from human platelets was expressed permanently in Rat-1 fibroblasts. A series of clones that varied in expression of the receptor from 0 to 3.5 pmol/mg of membrane protein were isolated. We have demonstrated recently in cells of one of these clones (1C) that the alpha 2-C10 receptor interacts directly with two distinct pertussis toxin-sensitive G-proteins, Gi2 and Gi3 (Milligan, G., Carr, C., Gould, G. W., Mullaney, I., and Lavan, B.E. (1991) J. Biol. Chem. 266, 6447-6455). High affinity GTPase activity in membranes of cells from the various clones was stimulated by the addition of the alpha 2-adrenergic agonist UK14304, defining that the receptor coupled productively to the G-protein signaling system. Maximal stimulation of high affinity GTPase activity correlated with the levels of receptor expressed. Clones expressing the receptor also demonstrated agonist-mediated inhibition of adenylylcyclase. Futhermore, the alpha 2-C10 receptor in one clone (1C), but not other clones, promoted a marked stimulation in the generation of water-soluble products derived from phosphatidylcholine. The concentration of UK14304 required to produce half-maximal regulation of GTPase activity (20-30 nM), of forskolin-amplified adenylylcyclase activity (30-40 nM), and of choline generation (30-40 nM) were similar. Transphosphatidylation experiments with cells of clone 1C indicated that the receptor-mediated hydrolysis of phosphatidylcholine was via the action of a phospholipase D. All of these effects were attenuated by pretreatment of the cells with pertussis toxin. Dose-effect curves of pertussis toxin-treatment demonstrated similar effective concentrations of the toxin in causing endogenous ADP-ribosylation of both Gi2 and Gi3, inhibition of receptor-stimulated GTPase activity, and phospholipase D activity. Receptor activation of phospholipase D activity was not dependent upon prior phospholipase C-dependent activation of protein kinase C, as alpha 2-adrenergic stimulation of inositol phosphate production was negligible and the presence of the selective protein kinase C inhibitor RO-31-8220, at concentrations up to 10 microM, had no effect on UK14304-mediated production of phosphatidylbutanol. These results demonstrate that expression of the alpha 2-C10 receptor in a heterologous system can result in receptor regulation of signaling elements that appear not to be primary targets for the receptor in vivo. Such results are important in respect to recent observations that transfection of a single defined receptor into separate cell lines can lead to the regulation of distinct effector systems (Vallar, L., Muca, C., Magni, M., Albert, P., Bunzow, J., Meldolesi, J. and Civelli, O. (1990) J. Biol. Chem. 265, 10320-10326).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346392

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Disparate ligand-mediated Ca(2+) responses by wild-type, mutant Ser(200)Ala and Ser(204)Ala alpha(2A)-adrenoceptor: G(alpha15) fusion proteins: evidence for multiple ligand-activation binding sites.

Authors:  P J Pauwels; F C Colpaert
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Gi3 does not contribute to the inhibition of adenylate cyclase when stimulation of an alpha 2-adrenergic receptor causes activation of both Gi2 and Gi3.

Authors:  S J McClue; E Selzer; M Freissmuth; G Milligan
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

3.  A constitutively active mutant of the alpha 1B-adrenergic receptor can cause greater agonist-dependent down-regulation of the G-proteins G9 alpha and G11 alpha than the wild-type receptor.

Authors:  T W Lee; A Wise; S Cotecchia; G Milligan
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

4.  Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoceptor by ligands that act as inverse agonists.

Authors:  T W Lee; S Cotecchia; G Milligan
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

5.  Cell type influences the molecular mechanisms involved in hormonal regulation of ERG K+ channels.

Authors:  Luis Carretero; Francisco Barros; Pablo Miranda; Jorge Fernández-Trillo; Angeles Machín; Pilar de la Peña; Pedro Domínguez
Journal:  Pflugers Arch       Date:  2012-03-14       Impact factor: 3.657

6.  Activation of LA-N-2 cell phospholipase D by amyloid beta protein (25-35).

Authors:  I N Singh; G Sorrentino; J N Kanfer
Journal:  Neurochem Res       Date:  1998-10       Impact factor: 3.996

7.  Stimulation of human thyroid growth via the inhibitory guanine nucleotide binding (G) protein Gi: constitutive expression of the G-protein alpha subunit Gi alpha-1 in autonomous adenoma.

Authors:  E Selzer; A Wilfing; A Schiferer; M Hermann; B Grubeck-Loebenstein; M Freissmuth
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

8.  Resistance of macrophages to Mycobacterium avium is induced by alpha2-adrenergic stimulation.

Authors:  Kelly E Weatherby; Bruce S Zwilling; William P Lafuse
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

9.  The mechanism of action of alpha 2-adrenoceptors in human isolated subcutaneous resistance arteries.

Authors:  N A Parkinson; A D Hughes
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

10.  Stimulation of high-affinity GTPase activity and cholera toxin-catalysed [32P]ADP-ribosylation of Gi by lysophosphatidic acid (LPA) in wild-type and alpha 2C10 adrenoceptor-transfected Rat 1 fibroblasts.

Authors:  C Carr; M Grassie; G Milligan
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.